Xeltis’ Post

Delighted to have contributed an article on transparency in #RealWorldEvidence for this #CMRO special issue - see https://lnkd.in/ePSH32C5 The breadth of populations, interventions, outcomes and methodologies covered by the studies published in this issue alone, shows the tremendous potential value of #RWE in informing healthcare decision-making. #realworldevidence #realworlddata #patientcare #RWE #publications  Oxford PharmaGenesis

We are excited to share that the Zamplo team is attending the 30th annual International Society for Quality of Life Research (ISOQOL) Conference! ISOQOL creates a global space for researchers, clinicians, health care professionals, industry professionals, consultants, and patient research partners advancing health related quality of life research (HRQL) to come together to discuss the patient perspective to health research, care and policy. This year's conference will focus on identifying barriers that limit the use of PROs in patient care and work towards forming new practical solutions. The Zamplo team will be presenting “Radiation PATH: Evaluating A Mobile Health-Based Radiation Oncology Patient Assessment Tool” at the conference. To learn more about how Zamplo Research can be used to advance HRQL clinical research and care, visit https://hubs.ly/Q024GtHK0 #healthresearch #clinicalresearch #PROMs #PROs #datacollection #patientengagement #researchparticipant #qualityoflife #QoL #ISOQOL #ePROS #patientreportedoutcomes #clinicalcare

From May 30 to 31, don’t miss the panel of international experts and attend sessions on AF ablation, ventricular arrythmias and several cases sessions. 👉 Take a look at the synoptic: https://lnkd.in/gks5sBnA The course directors : Jean paul Albenque, Clement Bars, MD, Sonia Busch, K.R. Julian Chun, Deisenhofer Isabel, Tom De Potter, Franck Halimi, Julien Seitz, MD The partners of the Rhythm 2024 congress : Medtronic, Abbott, MicroPort, Biosense Webster, Volta, Boston Scientific, GE HealthCare, Bristol Myers Squibb #Rhythm2024 #RhythmCongress #Arrhythmias #HeartFailure #Rhythmology

Vicore Pharma AB is pleased to announce positive final results from the Phase 2a AIR trial demonstrating that buloxibutid improves lung function over 36 weeks in patients with idiopathic pulmonary fibrosis (#IPF). These encouraging results were presented yesterday by Toby Maher, Keck School of Medicine of USC, as a late-breaking oral session at the American Thoracic Society International Congress (#ATS2024). Vicore will be discussing the results in more detail during a webinar on Wednesday 5/22 at 10:00 ET/16:00 CET. You can register for the webinar here: https://lnkd.in/eKp8xYGj #pulmonaryfibrosis #biotechnews #respiratory #clinicaldata

Clopidogrel versus aspirin monotherapy beyond 1 year after PCI: STOPDAPT-2 five-year results #EAPCI/PCR Journal Club: Nicola Ryan reviews the results of this trial presented at #TCT2023 and simultaneously published in JACC https://lnkd.in/e6knnvrH #DAPT #interventionalcardiology #clinicaltrial #clinicaltrials

We're so pleased to report positive final results for Vicore Pharma AB's AT2 receptor agonist, buloxibutid, in the Phase 2a AIR study in IPF, reflecting disease-modifying potential. We believe that agonizing an upstream pathway impacting precursor alveolar epithelial type II cells is a excellent approach to this tough disease and are looking forward to initiating the Phase 2b ASPIRE study to advance this exciting molecule! #ATS2024 #IPF #PulmonaryFibrosis

Ananda Developments Plc (AQSE:ANA) finance director Jeremy Sturgess-Smith shares promising results from preclinical studies investigating the efficacy of MRX1 in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF). Sturgess-Smith explained that Ananda Developments acquired MRX Medical, the company that owns the MRX1 IP, last year. The company specialises in chronic inflammatory pain conditions and cannabis-based medicinal treatments. The study shows that dosing MRX1 in mice with heart failure and preserved ejection fraction can bring heart and lung weight back to healthy levels and significantly reduce heart failure compounds. Sturgess-Smith emphasised the high unmet medical need in treating heart failure, with limited options beyond diet and exercise. Ananda Developments aims to include MRX1 as part of its treatment portfolio, alongside its existing two Phase II trials investigating... Watch at #Proactive #ProactiveInvestors http://ow.ly/JkEF105ye5S

The EffPac trial was a prospective, multicentre, randomised controlled trial (RCT) that enrolled 171 patients of Rutherford category two to four with medium-length femoropopliteal lesions. Patients were allocated 1:1 to either Luminor drug-coated balloon (DCB) angioplasty or plain balloon angioplasty (POBA). The long-term results showed a high efficacy (fTLR 82.1%) and statistically superior primary patency for Luminor over POBA, and importantly, showed that DCB use resulted in no safety differences between the two groups. The investigators achieved on-site patient visits in 50% of the recruited patients after five years. “These data are pretty rare […] and actually after this whole discussion about safety of paclitaxel-coated DCBs, I think [this trial] really adds important data,” Prof. Dr. Ulf Teichgräber (Jena, Germany) tells Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2023 annual meeting. This video is sponsored by iVascular https://lnkd.in/etEv2dzm #EffPac #DCB #femoropoplitea #endovascular

What makes a robust iPSC-derived atrial model? If you're looking to develop high-quality, chamber-specific cardiac models for research and toxicity screening, then we can help. Listen to this excerpt of our Senior Scientific Support Manager (and cardiomyocytes expert) Steven Broadbent as he distils over a decade of Axol Bioscience expertise into four steps that can produce a robust iPSC-derived atrial model. This is taken from Steven's masterclass "Building chamber-specific cardiac models with iPSCs" which covers: • Our learnings from over a decade in the cardiac iPSC space • The functional data supporting our atrial and ventricular cardiomyocytes (for use in chamber-specific models) • A look to the future of cardiotoxicity models Click here to access the full webinar recording: https://hubs.la/Q02xc6sG0 If you're working with iPSC-derived cardiomyocytes and would like to discuss how Axol Bioscience could help you to unlock the benefits of iPSC technology, get in touch at operations@axolbio.com #iPSCs #cardiotoxicity #CiPA #DrugDiscovery #AtrialFibrillation

The multi-national RESOLVE-AF trial enrolled its first patient in the EU today as Dr. Max Liebregts and Dr. Lucas Boersma completed the first case at St. Antonius Hospital Nieuwegein, The Netherlands. Boersma, the European PI for the international trial said, “I’m excited to participate in this study to evaluate Cortex’s EGF mapping as a promising approach to identify extra-pulmonary vein EGF sources and their phenotypes." RESOLVE-AF is a prospective, international, multi-center trial to evaluate the use of the OptiMap™ System and OptiMap™ Catheter to identify extra-pulmonary vein EGF sources and their phenotypes. #EPeeps, #AFablation